Scarica l'app Stockscreener
3.00
3.85%
-0.12
Dopo l'orario di chiusura:
3.00
Precedente Chiudi:
$3.12
Aprire:
$3.18
Volume 24 ore:
1.03M
Relative Volume:
0.74
Capitalizzazione di mercato:
$190.67M
Reddito:
$139.77M
Utile/perdita netta:
$-97.62M
Rapporto P/E:
-1.8987
EPS:
-1.58
Flusso di cassa netto:
$-61.71M
1 W Prestazione:
+34.53%
1M Prestazione:
+75.44%
6M Prestazione:
+88.68%
1 anno Prestazione:
+36.36%
Intervallo 1D:
$2.9701
$3.25
Intervallo di 1 settimana:
$2.25
$3.54
Portata 52W:
$0.9897
$3.54
Macrogenics Inc Stock (MGNX) Company Profile
Nome
Macrogenics Inc
Settore
Industria
Telefono
301-251-5172
Indirizzo
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
3.00 | 190.67M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2024-11-07 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-31 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-05-10 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Downgrade | Stifel | Buy → Hold |
| 2024-05-10 | Downgrade | TD Cowen | Buy → Hold |
| 2024-04-26 | Iniziato | B. Riley Securities | Buy |
| 2024-04-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-03-04 | Reiterato | BTIG Research | Buy |
| 2024-02-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-11-22 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-11-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Downgrade | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-02-28 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-04 | Iniziato | SMBC Nikko | Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Buy |
| 2021-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-12 | Aggiornamento | Barclays | Underweight → Overweight |
| 2020-12-22 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-03 | Downgrade | Citigroup | Buy → Neutral |
| 2020-06-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2019-12-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Guggenheim | Neutral |
| 2019-02-07 | Aggiornamento | Citigroup | Sell → Buy |
| 2019-02-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-02-06 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Downgrade | Citigroup | Neutral → Sell |
| 2018-12-10 | Downgrade | Raymond James | Outperform → Underperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-05-31 | Iniziato | Evercore ISI | Outperform |
| 2018-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-31 | Iniziato | Raymond James | Outperform |
Mostra tutto
Macrogenics Inc Borsa (MGNX) Ultime notizie
MacroGenics at Barclays Conference: Strategic Therapeutic Focus By Investing.com - Investing.com Canada
MGNX: Multiple clinical milestones and strategic updates expected in 2026, backed by strong partnerships - TradingView
MacroGenics (NASDAQ:MGNX) Price Target Raised to $4.00 at Barclays - Defense World
MacroGenics (MGNX) Loss Of US$74.6 Million Tests Bullish Loss‑Narrowing Narrative - Sahm
MacroGenics at Leerink Global Healthcare Conference: Strategic Pipeline Focus By Investing.com - Investing.com Canada
Stifel reiterates MacroGenics stock rating with $4 price target By Investing.com - Investing.com Nigeria
Stifel reiterates MacroGenics stock rating with $4 price target - Investing.com
MacroGenics Inc earnings missed by $0.03, revenue topped estimates - Investing.com Nigeria
Barclays Forecasts Strong Price Appreciation for MacroGenics (NASDAQ:MGNX) Stock - MarketBeat
MacroGenics (NASDAQ:MGNX) Announces Quarterly Earnings Results, Beats Estimates By $0.20 EPS - MarketBeat
Barclays Raises Price Target for Macrogenics (MGNX) to $4.00, Maintains 'Overweight' Rating | MGNX Stock News - GuruFocus
MacroGenics, Inc. 2025 Annual Report: Innovative Antibody-Based Cancer Therapeutics, Pipeline, and Risk Factors Overview - Minichart
MGNX Closes Up 45% On Wall Street Optimism For Experimental Cancer Therapies - Stocktwits
MacroGenics Q4 2025 Earnings: Loss Below Estimates, Revenue Beats ForecastNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures - Bitget
MacroGenics: Fourth Quarter Earnings Overview - Bitget
MacroGenics: Q4 Earnings Snapshot - marketscreener.com
MacroGenics : Corporate Overview March 2026 - marketscreener.com
Cancer biotech MacroGenics lines up 2026 trial data, funds into 2027 - Stock Titan
Chipmakers Recap: Can MacroGenics Inc expand its profit margins2026 Macro Moves & Low Risk Growth Stock Ideas - baoquankhu1.vn
Aug Breakouts: Can MacroGenics Inc disrupt its industryPortfolio Value Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Risk Off: Will MacroGenics Inc. stock deliver consistent dividends2025 Growth vs Value & Detailed Earnings Play Strategies - Naître et grandir
Aug Retail: Will MacroGenics Inc outperform the market in YEARJuly 2025 Macro Moves & Long-Term Growth Plans - baoquankhu1.vn
Trade Recap: Can MacroGenics Inc expand its profit marginsWeekly Volume Report & Long-Term Growth Stock Strategies - baoquankhu1.vn
MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Analysts - MarketBeat
MGNX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MacroGenics (MGNX) director Jay Siegel to step down after 2026 meeting - Stock Titan
MacroGenics, Inc. Announces Jay Siegel Not Stands for Re-Election as Class I Director, Effective February 25, 2026 - marketscreener.com
Whats the profit margin of MacroGenics IncEarnings Risk Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus
MacroGenics to Participate in Upcoming Investor Conferences - The Manila Times
Cancer drug developer MacroGenics lines up March investor talks - Stock Titan
FDA Partially Pauses Cancer Drug Trial After Patient Death - National Today
Why is MacroGenics stock sinking Tuesday? - MSN
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates - MSN
MacroGenics stock falls after FDA places partial clinical hold - Investing.com South Africa
MacroGenics stock falls after FDA places partial clinical hold By Investing.com - Investing.com Australia
MacroGenics (MGNX) Faces FDA Setback with Partial Hold on Lorige - GuruFocus
MacroGenics stock drops after FDA partial hold (MGNX:NASDAQ) - Seeking Alpha
FDA Places Partial Clinical Hold on MacroGenics Trial - TipRanks
FDA Imposes Partial Clinical Hold on MacroGenics' (MGNX) Study - GuruFocus
MacroGenics Pauses Cancer Drug Trial After Safety Issues - National Today
MacroGenics Pauses Enrollment Of Participants In LINNET Trial On FDA's Partial Clinical Hold - RTTNews
MacroGenics says FDA places partial clinical hold on Phase 2 LINNET study - TipRanks
Why Is MacroGenics Stock Sinking Tuesday? - Bitget
FDA halts new enrollment in MacroGenics (NASDAQ: MGNX) LINNET study - Stock Titan
Macrogenics announces pausing of enrollment of new study participants in Linnet trial - marketscreener.com
MacroGenics Faces Partial Clinical Hold from FDA on LINNET Study of Lorigerlimab in Gynecologic Cancers - Quiver Quantitative
FDA halts new enrollment in cancer trial after severe side effects - Stock Titan
Panic Selling: Will MacroGenics Inc outperform the market in YEAR2025 Performance Recap & Weekly Setup with High ROI Potential - baoquankhu1.vn
Macrogenics Inc Azioni (MGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):